Indirab Rabies Vaccine Administration at Chughtai Lab

Indirab (Rabies) at Chughtai Lab

Rabies is an acute, progressive, and virtually fatal viral encephalomyelitis caused by the rabies virus, a member of the Lyssavirus genus within the Rhabdoviridae family. Because the rabies virus targets the central nervous system, causing irreversible neurological damage once clinical symptoms manifest, timely immunoprophylaxis is the only effective means of survival. Indirab is a highly purified Vero cell rabies vaccine (PVRV) containing inactivated Pitman-Moore strain rabies virus. It is widely recognized for its high immunogenicity, purity, and safety profile. Chughtai Lab, Pakistan’s premier diagnostic and healthcare network, offers professional and reliable Indirab vaccine administration across its extensive network of medical centers and laboratories, ensuring that patients have immediate access to this life-saving preventive intervention.

The Indirab vaccine works by stimulating the body’s immune system to produce active neutralizing antibodies against the rabies virus glycoprotein. These antibodies neutralize the virus at the site of inoculation before it can gain entry into the peripheral nerves and travel to the spinal cord and brain. Administering Indirab as part of a post-exposure prophylaxis (PEP) protocol, or as pre-exposure prophylaxis (PrEP), provides robust immunological protection. Chughtai Lab utilizes state-of-the-art cold chain management systems to preserve the potency and efficacy of the vaccine from storage to administration. Understanding the clinical indications, administration schedules, and safety protocols of Indirab is essential for patients seeking protection against this deadly zoonotic disease.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the safety and efficacy of the Indirab vaccine administration. Patients should follow these guidelines before receiving the injection at Chughtai Lab:

• Wound Care First: If you have been bitten or scratched by an animal, immediately wash the wound thoroughly with soap and running water for at least 15 minutes. This is the most critical first-aid step to physically remove viral particles.
• No Fasting Required: There is no need to fast before receiving the Indirab vaccine. Patients are encouraged to eat a light meal and stay hydrated to prevent dizziness or vasovagal episodes.
• Medical History Disclosure: Inform the healthcare professional at Chughtai Lab of any known allergies, especially to polymyxin B, neomycin, or streptomycin, as trace amounts may be present in the vaccine.
• Medication Review: Disclose all current medications, particularly immunosuppressive therapies, systemic corticosteroids, or chemotherapy, which may impair the body’s immune response to the vaccine.
• Pregnancy and Lactation: Inform the clinician if you are pregnant or breastfeeding. While rabies vaccination is safe and mandatory post-exposure, special clinical documentation is maintained.
• Previous Vaccinations: Provide any records of prior rabies vaccinations, as this significantly alters the required dosage schedule.

During the Procedure

When you arrive at Chughtai Lab for your Indirab vaccination, you will experience a highly professional, sterile, and streamlined clinical process:

• Clinical Assessment: A qualified healthcare professional will assess the category of animal exposure (Category I, II, or III) to determine if Rabies Immunoglobulin (RIG) is also required alongside the Indirab vaccine.
• Patient Positioning: The patient is comfortably seated. For adults and older children, the injection is administered in the deltoid muscle of the upper arm. For infants and toddlers, the anterolateral aspect of the thigh is utilized. The gluteal region must never be used, as fat tissue reduces vaccine absorption and efficacy.
• Aseptic Reconstitution: The nurse will aseptically reconstitute the freeze-dried Indirab vaccine powder with the provided sterile diluent, ensuring complete dissolution of the antigen.
• Administration: The injection site is sanitized with an alcohol swab, and the vaccine is administered intramuscularly (or intradermally, depending on the specific clinical protocol prescribed).
• Post-Injection Observation: Patients are advised to remain in the waiting area for 15 to 30 minutes post-administration to monitor for any immediate allergic reactions or anaphylaxis.
• Schedule Documentation: The patient is provided with a personalized vaccination card detailing the exact dates for the remaining doses of the multi-dose regimen.

When is Indirab (Rabies) Performed?

Post-Exposure Prophylaxis (PEP) After Animal Bites

Post-exposure prophylaxis is the primary clinical indication for Indirab administration. It is initiated immediately after a bite from a suspected rabid animal, such as a dog, cat, bat, fox, or jackal. Because rabies has a variable incubation period, starting the Indirab vaccine series as soon as possible after exposure is critical to neutralizing the virus before it reaches the central nervous system.

Pre-Exposure Prophylaxis (PrEP) for High-Risk Individuals

Pre-exposure prophylaxis is recommended for individuals at high risk of encountering the rabies virus. This includes veterinarians, animal handlers, laboratory personnel working with live rabies virus, wildlife officers, and individuals traveling to or living in highly endemic areas with limited access to immediate medical care. PrEP simplifies post-exposure management by eliminating the need for rabies immunoglobulin and reducing the number of vaccine doses required upon re-exposure.

Scratches and Licks on Broken Skin

Many patients mistakenly believe that only deep bites require vaccination. However, the rabies virus is transmitted through saliva. Minor scratches, abrasions without bleeding, or licks on broken skin (Category II exposure) provide an entry point for the virus. Administering Indirab in these scenarios is vital to prevent viral transmission and ensure complete patient safety.

Re-exposure Immunization for Previously Vaccinated Individuals

Individuals who have previously completed a full, documented course of pre-exposure or post-exposure rabies vaccination require a modified regimen if they are exposed to a rabid animal again. In these cases, Indirab is administered as a booster (typically two doses on Days 0 and 3). This rapid booster response reactivates immunological memory, eliminating the need for expensive and scarce rabies immunoglobulin.

Travelers Visiting Rabies-Endemic Regions

International and domestic travelers visiting remote areas of Pakistan or other rabies-endemic countries are advised to receive pre-exposure vaccination with Indirab. This is particularly important for children, who are more likely to play with animals, sustain unrecognized bites, or fail to report animal contact, making preventive immunization a key travel safety measure.

What Does Indirab (Rabies) Prevent and Protect Against?

The administration of the Indirab vaccine at Chughtai Lab serves several critical preventive and protective clinical functions:

• Prevention of rabies virus entry into the peripheral nervous system.
• Stimulation of active humoral immunity through the production of specific neutralizing antibodies.
• Establishment of long-term immunological memory against the rabies virus glycoprotein.
• Protection against Category II animal exposures involving minor scratches or abrasions.
• Protection against Category III animal exposures involving deep transdermal bites.
• Post-exposure prophylaxis following stray dog bites, which represent the main vector of rabies in Pakistan.
• Prophylaxis following scratches or bites from domestic pets with unverified vaccination status.
• Prevention of viral replication at the site of inoculation.
• Protection for veterinary professionals handling potentially rabid animals daily.
• Immunization for laboratory staff processing diagnostic specimens containing rabies virus.
• Prevention of rabies transmission through animal saliva contact with mucous membranes.
• Reduction of the public health burden associated with rabies-related mortality.
• Safe immunization for pediatric patients who are highly vulnerable to animal attacks.
• Safe administration for geriatric patients requiring post-exposure intervention.
• Safe use during pregnancy when post-exposure prophylaxis is clinically indicated.
• Safe use during lactation to protect both mother and infant from potential exposure risks.
• Elimination of the need for rabies immunoglobulin (RIG) during subsequent re-exposures.
• Prevention of progressive, fatal encephalomyelitis.
• Replacement of outdated, nerve-tissue-derived vaccines with a highly purified Vero cell vaccine.
• Rapid onset of protective antibody titers, typically achieved within 7 to 14 days of the first dose.
• Maintenance of protective antibody levels (equal to or greater than 0.5 IU/mL) as recommended by the World Health Organization.
• Protection for travelers exploring rural or remote areas with limited healthcare infrastructure.
• Provision of a highly tolerated vaccine with minimal risk of severe systemic adverse events.
• Ensuring peace of mind and psychological relief for patients and families after animal bite incidents.

Turnaround Time and Report Access at Chughtai Lab

Because Indirab is an immunization service rather than a diagnostic test, there is no laboratory turnaround time or diagnostic report to wait for. Instead, documentation is immediate and highly structured. Upon receiving your first dose of Indirab at Chughtai Lab, you will be issued an official, physical Rabies Vaccination Card. This card is a critical medical document that records the vaccine brand name (Indirab), batch number, expiration date, date of administration, and the signature of the administering clinician.

Additionally, Chughtai Lab logs all vaccination details into its secure electronic medical records (EMR) system. Patients can access their immunization history, view scheduled dates for subsequent doses, and download digital copies of their vaccination records through the Chughtai Lab mobile application or the official online portal. Automated SMS reminders are also sent to patients to ensure they do not miss their scheduled follow-up doses, which is crucial for maintaining the efficacy of the vaccine regimen.

Indirab Findings and Administration Overview

The following table outlines the clinical parameters evaluated, expected normal responses, and potential abnormal findings or adverse reactions associated with Indirab vaccine administration:

Structure / Parameter Evaluated	Normal Findings / Expected Response	Possible Abnormal Findings / Adverse Reactions
Injection Site (Local Reaction)	Mild, transient erythema, slight swelling, or mild tenderness at the injection site resolving within 24-48 hours.	Severe localized pain, persistent swelling, induration, or sterile abscess formation.
Systemic Immune Response	No systemic symptoms, or mild, self-limiting low-grade fever, headache, and mild malaise.	High-grade fever, severe chills, generalized myalgia, or severe arthralgia.
Allergic / Hypersensitivity Reaction	No allergic response; normal tolerance of the vaccine components.	Immediate hypersensitivity, urticaria, pruritus, angioedema, or anaphylaxis (extremely rare).
Neurological Status	Normal neurological function; no paresthesia, weakness, or sensory changes.	Guillain-Barré syndrome or acute disseminated encephalomyelitis (exceedingly rare).
Antibody Titer (Immunogenicity)	Serum neutralizing antibody titer equal to or greater than 0.5 IU/mL, indicating protective immunity.	Inadequate antibody response (titer less than 0.5 IU/mL), typically seen in severely immunocompromised individuals.
Gastrointestinal System	No gastrointestinal symptoms.	Mild nausea, abdominal pain, diarrhea, or vomiting post-administration.
Lymphatic System	No lymphadenopathy.	Transient regional lymphadenopathy (swelling of lymph nodes near the injection site).
Schedule Adherence	Completion of all doses on the exact scheduled days (e.g., Days 0, 3, 7, 14, 28).	Delayed or missed doses, which may compromise the development of active protective immunity.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Indirab (Rabies)?

• Experienced Healthcare Professionals: Administered by highly trained nursing staff skilled in aseptic injection techniques and emergency management.
• Cold Chain Integrity: Chughtai Lab maintains strict temperature-controlled storage (2°C to 8°C) for all vaccines, ensuring maximum potency and safety of Indirab.
• Nationwide Network: Convenient access to rabies vaccination services across Pakistan, with numerous locations in Lahore, Karachi, Islamabad, and other major cities.
• Patient-Focused Care: Compassionate support for patients experiencing stressful animal bite incidents, with clear guidance on wound care and vaccination schedules.
• Digital Vaccination Tracking: Automated SMS reminders and digital records via the Chughtai Lab App to help patients adhere strictly to their multi-dose immunization schedule.
• Quality Diagnostic Services: Comprehensive healthcare ecosystem allowing seamless integration of laboratory testing, wound assessment, and vaccination.
• Comfortable and Safe Environment: Modern, clean, and hygienic injection rooms designed to minimize patient anxiety and ensure a safe clinical experience.
• Commitment to Accurate Diagnosis and Prevention: Adherence to international WHO guidelines for rabies post-exposure and pre-exposure prophylaxis.